2024-518833-27-00已完成1 期
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Doug Williamson, MD
Scientific
Quralis Corp.
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Three Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low Dose Ritonavir (RTV), a Drug-Drug Interaction Study Between IV DNV/Oral Low Dose RTV and Oral Cyclosporine, and the Absolute Bioavailability of IV DNV as Compared to DNV Tablets Together With Oral Low Dose RTV in Healthy Adult VolunteersChronic Hepatitis CJaundice10047438NL-OMON37643Hoffmann-La Roche29
进行中（未招募）
1 期
A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary AngioedemaHereditary AngioedemaMedDRA version: 12.1Level: LLTClassification code 10019860Term: Hereditary angioedemaEUCTR2010-022716-39-DEDyax Corp.22
招募中
3 期
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Through 11 Years of AgeCystic Fibrosis2024-513754-29-00Vertex Pharmaceuticals Inc.15
进行中（未招募）
1 期
Evaluation of VX-445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 YearsCystic FibrosisEUCTR2018-001695-38-GBVertex Pharmaceuticals Incorporated56
进行中（未招募）
1 期
Evaluation of VX-445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 YearsCystic FibrosisEUCTR2018-001695-38-IEVertex Pharmaceuticals Incorporated56